GuruPSonpavdeMD

Oncology • Orlando, FL

Genitourinary Oncology

GU Oncology & Phase I Director AdventHealth Cancer Institute University of Central Florida Orlando, FL, USA

Join to view full profile

Dr. Sonpavde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sonpavde's full profile

Already have an account?

Office
AdventHealth Cancer Institute
2501 N Orange Ave, Ste 681
Orlando, FL 32804
Phone+1 407-303-2024

Fax+1 407-303-2038
Is this information wrong?

Summary

Current and Emerging Agents to Treat Advanced Bladder Cancer

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelia

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelial Carcinoma

Immunotherapy Outcomes in Pure vs Mixed Urothelial Carcinoma Histology

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Nassau University Medical CenterResidency, Internal Medicine, 1992 - 1995
Christian Medical College VelloreClass of 1990

Certifications & Licensure

CT State Medical License Current
FL State Medical License 2022 - 2024
MA State Medical License 2017 - 2024
RI State Medical License 2020 - 2020
AL State Medical License 2012 - 2017
TX State Medical License 2003 - 2013
AZ State Medical License 2001 - 2003
TN State Medical License 1999 - 2002
IN State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Vidaza to Restore Hormone Thx Prostate Start of enrollment: 2006 Apr 01
Completed
Phase 2
Phase II Sunitinib Prog Met AIPC Start of enrollment: 2007 Mar 01
Completed
Phase 2
Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
Completed
Phase 2
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal Start of enrollment: 2011 Apr 01
Terminated
Phase 2
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Unknown status
Phase 1, Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Active, not recruiting
Phase 3
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 1
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 2
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment Start of enrollment: 2014 Apr 01
Completed
Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Active, not recruiting
Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Start of enrollment: 2014 Jul 01
Active, not recruiting
Phase 2
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2015 May 01
Terminated
Phase 1
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Apr 01
Active, not recruiting
Phase 2
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Start of enrollment: 2015 May 01
Completed
Phase 2
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2016 Oct 01
Terminated
Phase 2
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Start of enrollment: 2017 May 23
Withdrawn
Phase 2
Phase I Trial of PACE for Metastatic Prostate Cancer Start of enrollment: 2018 May 09
Withdrawn
Phase 1
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Start of enrollment: 2019 Feb 20
Active, not recruiting
Phase 1
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2021 Jan 21
Recruiting
Phase 2
Sacituzumab Govitecan Plus EV in Metastatic UC Start of enrollment: 2021 May 20
Recruiting
Phase 1
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients Start of enrollment: 2021 Apr 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Kyle M Rose, Heather L Huelster, Joshua J Meeks, Bishoy M Faltas, Guru P Sonpavde, Seth P Lerner, Jeffrey S Ross, Philippe E Spiess, G Daniel Grass, Rohit K Jain, Ashi...> ;Nature Reviews. Urology. 2023 May 22
Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Alicia K Morgans, Matthew D Galsky, Phoebe Wright, Zsolt Hepp, Nancy Chang, Candice L Willmon, Steve Sesterhenn, Yutong Liu, Guru P Sonpavde> ;Urologic Oncology. 2023 May 17
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in Pe...
Talal El Zarif, Amin H Nassar, Elio Adib, Bailey G Fitzgerald, Jiaming Huang, Tarek H Mouhieddine, Paul G Rubinstein, Taylor Nonato, Rana R McKay, Mingjia Li, Arjun Mi...> ;Journal of Clinical Oncology. 2023 May 16
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Kyle M Rose, Heather L Huelster, Joshua J Meeks, Bishoy M Faltas, Guru P Sonpavde, Seth P Lerner, Jeffrey S Ross, Philippe E Spiess, G Daniel Grass, Rohit K Jain, Ashi...> ;Nature Reviews. Urology. 2023 Mar 28
Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach.
Suryadipto Sarkar, Kong Min, Waleed Ikram, Ryan W Tatton, Irbaz B Riaz, Alvin C Silva, Alan H Bryce, Cassandra Moore, Thai H Ho, Guru Sonpavde, Haidar M Abdul-Muhsin, ...> ;Cancers. 2023 Mar 8
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde> ;Expert Opinion on Emerging Drugs. 2023 Mar 1
1 citations
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Zachary Quinn, Benjamin Leiby, Guru Sonpavde, Atish D Choudhury, Christopher Sweeney, David Einstein, Russell Szmulewitz, Oliver Sartor, Karen Knudsen, Eddy Shih-Hsin ...> ;Clinical Cancer Research. 2023 Jan 4
Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Abhishek Tripathi, Kira MacDougall, Guru P Sonpavde> ;Drugs. 2022 Nov 1
2 citations
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Hina Shah, Praful Ravi, Guru Sonpavde, Heather Jacene> ;Expert Review of Anticancer Therapy. 2022 Nov 1
10 citations
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
1 citations
Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
Matthew Mossanen, Amin H Nassar, Samantha M Stokes, Nieves Martinez-Chanza, Vivek Kumar, Pier Vitale Nuzzo, David J Kwiatkowski, Judy E Garber, Catherine Curran, Dory ...> ;Clinical Genitourinary Cancer. 2022 Dec 1
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
Guru P Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, Xiao X Wei, Kerry L Kilbridge, Richard J Lee, Evan Y Yu, Michael Thomas Schweizer, Robert B Montgo...> ;Cancer Immunology, Immunotherapy. 2023 Mar 1
4 citations
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
Hasibur Rehman, Darshan S Chandrashekar, Chakravarthi Balabhadrapatruni, Saroj Nepal, Sai Akshaya Hodigere Balasubramanya, Abigail K Shelton, Kasey R Skinner, Ai-Hong ...> ;JCI Insight. 2022 Aug 22
2 citations
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchko...> ;Clinical Genitourinary Cancer. 2022 Dec 1
Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
Alicia K Morgans, Simrun Grewal, Zsolt Hepp, Rupali Fuldeore, Shardul Odak, Cynthia Macahilig, Alicia C Shillington, Guru Sonpavde> ;Clinical Genitourinary Cancer. 2022 Dec 1
4 citations
Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials.
Irbaz B Riaz, Mahnoor Islam, Ahsan Masood Khan, Syed Arsalan Ahmed Naqvi, Rabbia Siddiqi, Kaneez Zahra Rubab Khakwani, Noureen Asghar, Waleed Ikram, Syed A Hussain, Pa...> ;The American Journal of Medicine. 2022 Aug 1
3 citations
Targetingalterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Sumanta K Pal, Diederik M Somford, Petros Grivas, Srikala S Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T Fleming, Seth P Lerner, Yohann Loriot, Jean ...> ;Future Oncology. 2022 Jul 1
Tivozanib for the treatment of advanced renal cell carcinoma.
Jonathan Chatzkel, Brian Ramnaraign, Guru Sonpavde> ;Expert Opinion on Pharmacotherapy. 2022 Jul 1
1 citations
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as anvaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.
Raj Satkunasivam, Kelvin Lim, Bin S Teh, Jonathan Guzman, Jun Zhang, Andrew Farach, Shu-Hsia Chen, Christopher Jd Wallis, Eleni Efstathiou, Nestor F Esnaola, Guru P So...> ;Future Oncology. 2022 Aug 1
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
Tomi Jun, Noah M Hahn, Guru Sonpavde, Constantine Albany, Gary R MacVicar, Ralph Hauke, Mark Fleming, Theodore Gourdin, Bagi Jana, William K Oh, Patricia Taik, Huan Wa...> ;The Oncologist. 2022 Jun 8
2 citations
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchko...> ;Clinical Genitourinary Cancer. 2022 Oct 1
1 citations
Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National ...
Kenan Celtik, Kelvin Lim, Furkan Dursun, Jiaqiong Xu, Zachary Klaassen, Jun Zhang, Eleni Efstathiou, Guru Sonpavde, Christopher Wallis, Raj Satkunasivam> ;Clinical Genitourinary Cancer. 2022 Jun 1
3 citations
TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3β/β-catenin signalling.
Song Gao, Shuaibin Wang, Zhiying Zhao, Chao Zhang, Zhicao Liu, Ping Ye, Zhifang Xu, Baozhu Yi, Kai Jiao, Gurudatta A Naik, Shi Wei, Soroush Rais-Bahrami, Sejong Bae, W...> ;Nature Communications. 2022 May 19
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhib...
Praful Ravi, Arvind Ravi, Irbaz B Riaz, Dory Freeman, Catherine Curran, Charlene Mantia, Bradley A McGregor, Kerry L Kilbridge, Chong-Xian Pan, Michelle Pek, Yukti Cho...> ;The Oncologist. 2022 May 6
1 citations
Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database.
Furkan Dursun, Kelvin Lim, Robert S Svatek, Jiaqiong Xu, Ziad M El-Zaatari, Evan P Wenker, Zachary W Klaassen, Ahmed M Mansour, Taliah Muhammad, Eleni Efstathiou, Guru...> ;Cancer Medicine. 2022 Nov 1
Join now to see all

Journal Articles

Development and Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
G Sonpavde, C S Higano, T M Beer, Annals of Oncology
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Richard S Foster, Lawrence H Einhorn, Christopher J Sweeney, Guru Sonpavde, Costantine Albany, Chandra K Flack, The Journal of Urology
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
Sonpavde G, Pond GR, Fougeray R, Bellmunt J., BJU Int, 2014

Lectures

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) Â± BMS-986205 in cisplatin-eligible muscle invasive bladder ...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

ASCO GU 2023: Practice Changing, Practice Reaffirming, Practice Informing and Emerging AdvancesFebruary 2023
GU Updates Abound at ASCO 2021June 2021
Cancer treatment: is a clinical trial right for youMarch 2019
Immunotherapy for cancer therapy: What you need to knowJanuary 2019
Join now to see all

Press Mentions

New Approaches in the Bladder-Sparing ParadigmMarch 20th, 2023
Immune Checkpoint Inhibitors for Patients Living with HIV: Safe and Effective in Metastatic NSCLCNovember 11th, 2022
GU Updates Abound at ASCO 2021June 14th, 2021